

BOTULINUM TOXINS PRIOR AUTHORIZATION FORM



Keystone First
Community HealthChoices

PERFORMRxSM
Next Generation Pharmacy Benefits

(form effective 1/6/2025)

Fax to PerformRxSM at **1-855-851-4058**, or to speak to a representative call **1-866-907-7088**.

PRIOR AUTHORIZATION REQUEST INFORMATION			
<input type="checkbox"/> New request <input type="checkbox"/> Renewal request	Total # pages:	Name of office contact:	
Contact's phone number:		LTC facility contact/phone:	
PATIENT INFORMATION			
Patient name:		Patient ID #:	DOB:
Street address:		Apt #:	City/state/zip:
PRESCRIBER INFORMATION			
Prescriber name:		Specialty:	
State license #:	NPI:	MA Provider ID #:	
Street address:		Suite #:	City/state/zip:
Phone:		Fax:	
CLINICAL INFORMATION			
Product requested: <input type="checkbox"/> Botox (preferred with clinical PA required) <input type="checkbox"/> Dysport (preferred with clinical PA required) <input type="checkbox"/> Myobloc (non-preferred) <input type="checkbox"/> Xeomin (non-preferred)			
Strength:	Injection site(s) and dose per site:		Qty requested:
Diagnosis (submit documentation):			DX code (required):
PHARMACY INFORMATION (Prescriber to identify the pharmacy that is to dispense the medication):			
Deliver to: <input type="checkbox"/> Patient's Home <input type="checkbox"/> Physician's Office <input type="checkbox"/> Patient's Preferred Pharmacy Name:			
Pharmacy Phone #:		Pharmacy Fax #:	
<input type="checkbox"/> I acknowledge that the patient agrees with the pharmacy chosen for delivery of this medication.			
INITIAL REQUESTS (Complete questions applicable to drug requested and patient's diagnosis):			
1. Request for a non-preferred agent (Myobloc or Xeomin): Does the patient have a history of trial and failure, contraindication, or intolerance of the preferred Botulinum Toxins that are FDA-approved for the patient's diagnosis and age? Check all that apply. <input type="checkbox"/> Botox <input type="checkbox"/> Dysport <input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> N/A <i>Submit documentation of all medications tried and outcomes.</i>			
2. Axillary hyperhidrosis: Does the patient have a history of trial and failure, contraindication, or intolerance of a topical agent such as 20% aluminum chloride? <input type="checkbox"/> Yes <input type="checkbox"/> No <i>List medications tried.</i>			
3. Overactive bladder: Does the patient have a history of trial and failure, contraindication, or intolerance of at least two other medications used to treat OAB? <input type="checkbox"/> Yes <i>List medication tried:</i> <input type="checkbox"/> No			
4. Urinary incontinence due to detrusor overactivity associated with a neurologic condition: Does the patient have a history of trial and failure, contraindication, or intolerance of at least one anticholinergic medication used to treat urinary incontinence? <input type="checkbox"/> Yes <input type="checkbox"/> No <i>List medications tried.</i>			
5. Migraine, Chronic: Check all of the following that apply to the patient and <i>submit documentation for each.</i> <input type="checkbox"/> Has a diagnosis of chronic migraine headache according to the current International Headache Society Classification of Headache Disorders that is not attributed to other causes including medication overuse <input type="checkbox"/> The requested agent is prescribed by, or in consultation with, one of the following specialists. Submit documentation of consultation, if applicable. <input type="checkbox"/> neurologist <input type="checkbox"/> headache specialist who is certified in headache medicine by the United Council for Neurologic Subspecialties (UCNS) <input type="checkbox"/> History of trial and failure, contraindication, or intolerance of an agent in at least two of the following drug classes used for migraine prevention: <input type="checkbox"/> anticonvulsants <input type="checkbox"/> beta blockers <input type="checkbox"/> antidepressants <input type="checkbox"/> calcitonin gene-related peptide (CGRP)-targeting migraine preventive therapies <i>List medications tried: _____</i>			
6. Spasticity, Chronic: Check all of the following that apply to the patient and <i>submit documentation for each.</i> <input type="checkbox"/> has spasticity that interferes with activities of daily living <input type="checkbox"/> has spasticity that is expected to result in joint contracture with future growth <input type="checkbox"/> if the patient has developed contractures, has been considered for surgical intervention <input type="checkbox"/> if ≥ 18 years of age: <input type="checkbox"/> has focal spasticity <input type="checkbox"/> has tried and failed, or has contraindication or intolerance of, an oral medication for spasticity <i>List medications tried: _____</i> <input type="checkbox"/> drug is being requested to either: <input type="checkbox"/> enhance function --OR-- <input type="checkbox"/> allow for additional therapeutic modalities to be employed <input type="checkbox"/> drug will be used in conjunction with other appropriate therapeutic modalities (e.g., OT, PT, gradual splinting)			
7. All other diagnoses: Submit documentation supporting the use of the requested agent for the patient's diagnosis and other treatments tried:			

RENEWAL REQUESTS

Check all of the following that apply to the patient and submit documentation for each:

- 1. Request for frequency of injection that is consistent with the dose and duration of therapy limits:
 - Patient showed a positive response to the medication
 - For treatment of chronic migraine headache:
 - Patient requires repeat injection to reduce the frequency, severity, or duration of symptoms
 - The requested agent is prescribed by, or in consultation with, one of the following specialists. Submit documentation of consultation, if applicable.
 - neurologist headache specialist who is certified in headache medicine by the United Council for Neurologic Subspecialties (UCNS)
 - For treatment of all other diagnoses:
 - Patient's symptoms returned to such a degree that repeat injection is required
- 2. Request for frequency of injection that exceeds the dose and duration of therapy limits:
 - Treatment was well tolerated but inadequate.
 - Peer-reviewed medical literature supports more frequent dosing as safe and effective for the diagnosis and requested dose (submit documentation of peer-reviewed medical literature)

PLEASE FAX COMPLETED FORM WITH REQUIRED CLINICAL DOCUMENTATION

Prescriber signature:	Date:
-----------------------	-------

Confidentiality Notice: The documents accompanying this telecopy may contain confidential information belonging to the sender. The information is intended only for the use of the individual named above. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or taking of any telecopy is strictly prohibited.